Multi-Cancer Studies
If it’s your first time on this website, please read the disclaimer section.
Jul 20 – Jul 27, 2026
IL-6 receptor inhibition promotes expansion of cytolytic CD4+ T cells after cellular immunotherapy.
BLOOD · Q1 JOURNAL - RANK #2/98TOP-TIER
This study aimed to investigate the immunological effects of IL-6 receptor (IL-6R) inhibition during allogeneic hematopoietic stem cell transplantation (HSCT), using single-cell RNA sequencing of patient samples from a prospective clinical trial comparing tocilizumab (TCZ) and placebo. Results showed IL-6R inhibition promoted Type-I IFN transcriptional programs and enhanced differentiation of cytolytic CD4+ T cells, including the Eomes+ subset, linked to favorable immunotherapy outcomes. Experimental systems confirmed IL-6 signaling attenuation improved anti-tumor effects by expanding cytolytic CD4+ T cells and reducing Th1/Th17 differentiation. These findings suggest IL-6R inhibition during HSCT may modulate immune responses to enhance cytolytic CD4+ T cells with implications for cancer immunotherapy optimization.
10.1182/blood.2025032420
Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies.
J IMMUNOTHER CANCER · Q1 JOURNAL - RANK #12/183TOP-TIER
Phase 1/2 IMC-C103C-101 (NCT03973333) evaluated the safety, PK/PD, biomarkers, and preliminary antitumor activity of the MAGE-A4×CD3 ImmTAC IMC‑C103C in HLA‑A*02:01 adults with previously treated advanced solid tumors via weekly IV step‑up dosing and mTPI‑2–guided dose escalation. Sixty‑eight patients (56 in 10 dose‑escalation cohorts, 12 in an ovarian carcinoma expansion; 64% OC) received 0.5–240 µg; DLT rates at the two highest dose levels were 1/6 and 2/10, with no treatment‑related discontinuations or deaths. A 15‑45‑140 µg regimen was selected for expansion, with mainly grade 1/2 cytokine‑mediated adverse events including CRS; 71% of tumors were MAGE‑A4+, median H‑score 16. Clinical and PD activity began at 15 µg and was more consistent at ≥90 µg, where MAGE‑A4+ OC showed deeper tumor and ctDNA reductions and a trend toward longer overall survival; IMC‑C103C was well tolerated up to 140 µg.
10.1136/jitc-2025-014638
Jul 06 – Jul 13, 2026
Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study.
JCO PRECIS ONCOL · Q1 JOURNAL - RANK #57/326
This Belgian investigator-initiated, open-label phase II trial prospectively evaluated afatinib in adults with advanced solid tumours carrying activating mutations in EGFR, HER2 or HER3 identified by next-generation sequencing. Using a Simon two-stage design, 45 previously treated patients were enrolled into three mutation-defined cohorts, and received continuous oral afatinib; the primary endpoint was objective response rate (ORR) with secondary endpoints including disease control rate (DCR), duration of response (DOR), progression-free and overall survival, and safety. Among 30 patients in the first cohort, ORR was 3.3% (one partial response) and DCR 23.3%; the second cohort showed ORR 28.6% (2/7 patients) with DORs of 6.6 and 15.4 months, while the third cohort (n = 8) had no responses. Afatinib’s safety profile matched previous reports, and while the primary endpoint was not met, the authors note clinically meaningful activity in two HER2-mutated cases warranting further study.
10.1200/PO-25-01198
Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma.
EUR J CANCER · Q1 JOURNAL - RANK #45/326
This open-label, multicenter phase I/Ib trial (NCT04261439) prospectively enrolled patients with advanced solid tumors or lymphoma who had previously received anti-PD-1 therapy to evaluate NIZ985, an IL-15 heterodimer, as monotherapy or combined with PD-1 inhibitors through dose-escalation and expansion cohorts. Patients received weekly subcutaneous NIZ985 at 8, 12, or 16 µg/kg, either alone or with spartalizumab/tislelizumab; safety endpoints included cycle-1 dose-limiting toxicities, full adverse-event profiling, and pharmacokinetic/pharmacodynamic assessments. Injection-site reactions, pyrexia, and transaminase increases were the most common adverse events; dose adjustments or interruptions were more frequent at 16 µg/kg, and exposure rose proportionally with dose while remaining unaffected by checkpoint blockade. The recommended dose for expansion was established at 12 µg/kg weekly (3 weeks-on/1 week-off), and although biological activity was observed, antitumor responses were limited in this heavily pretreated, PD-1-refractory population.
10.1016/j.ejca.2026.116899
Safety and feasibility of 5T4 antibody-coupled allogeneic NK cell therapy for solid tumors: a first-in-human phase 1 trial.
CANCER IMMUNOL IMMUN · Q1 JOURNAL - RANK #68/326
This phase 1, open-label, dose-escalation clinical trial evaluated the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of IBR854—a 5T4 antibody-coupled allogeneic NK cell therapy—in 19 patients with unresectable locally advanced or metastatic solid tumors. Participants received escalating intravenous doses across five cohorts, with safety and antitumor activity assessed (RECIST v1.1). No dose-limiting toxicities or anti-drug antibodies were detected; the disease control rate was 43.8% and median progression-free survival was 43 days. The study concluded that IBR854 therapy was feasible and safe, achieving disease stabilization in a subset of heavily pretreated patients.
10.1007/s00262-026-04481-1
Jun 22 – Jun 29, 2026
Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study.
EXP HEMATOL ONCOL · Q1 JOURNAL - RANK #6/98TOP-TIER
This phase 1 study (NCT04614740) evaluated eratrectinib (VC004) in patients with NTRK fusion-positive solid tumors using a 3+3 dose-escalation design (16 patients; 25-200 mg BID) and dose expansion (75 patients; 25-75 mg BID). Primary endpoints were safety, maximum tolerated dose (MTD=100 mg BID), and recommended phase 2 dose (RP2D=50 mg BID). At RP2D, objective response rate was 70% (21/30; 95%CI 50.6-85.3); grade ≥3 treatment-related adverse events occurred in 17.3% (13/75). Conclusions indicate eratrectinib has manageable safety and promising efficacy, warranting further confirmatory studies.
10.1186/s40164-026-00799-9
Jun 15 – Jun 22, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.
JCO PRECIS ONCOL · Q1 JOURNAL - RANK #57/326
In this prospective Phase II trial, researchers evaluated the selective WEE1 kinase inhibitor adavosertib in 33 patients with advanced BRCA1/2-mutant solid tumors. Patients were administered 300 mg daily for 5 days on, 2 days off, in 3-week cycles, with radiologic assessment every three cycles. The overall response rate was 3.3% (90% CI, 0.2–14.9), with an OS6 of 57.3% (90% CI, 41.9–72.7) and a PFS6 of 23.4% (90% CI, 10.7–36.2). Despite some disease stabilization and one partial response, the low response rate did not meet the primary endpoint.
10.1200/PO-25-00769
Efficacy of a structured rehabilitation program for patients with terminal cancer: A multicenter randomized controlled trial.
CANCER-AM CANCER SOC · Q1 JOURNAL - RANK #68/326
This multicenter randomized controlled trial across 19 Japanese hospices evaluated a structured rehabilitation program versus usual unstructured rehabilitation for terminal cancer patients with ECOG performance status 2-3 and life expectancy ≥3 weeks. Between July 2019 and February 2024, 130 patients were randomized (59 intervention, 71 control), with 77 included in the primary analysis. The mean change in modified Barthel Index was -1.31 (95% CI -10.89 to 8.08) in the intervention group versus -15.51 (95% CI -24.02 to -7.01) in controls (between-group difference 14.21, 95% CI 1.77-26.64, p=0.026), exceeding the minimal clinically important difference of 9.25. The authors conclude that structured rehabilitation maintains activities of daily living better than unstructured care and should be integrated into routine terminal cancer care.
10.1002/cncr.70485
Surufatinib plus toripalimab for patients with advanced solid tumors and disease progression after prior immunotherapy: an open-label multi-cohort phase 2 trial.
CANCER IMMUNOL IMMUN · Q1 JOURNAL - RANK #68/326
This phase 2 trial evaluated the efficacy and safety of surufatinib (250 mg orally, once daily) plus toripalimab (240 mg intravenously, every three weeks) in 28 adult patients with advanced solid tumors who progressed on prior PD-1/PD-L1 inhibitors. The primary endpoint was investigator-assessed objective response rate (ORR), which was 7.4% (95% CI: 0.9-24.3), with a disease control rate of 66.7% (95% CI: 46.0-83.5); median progression-free survival was 3.9 months (95% CI: 1.4-4.2) and overall survival was 13.0 months (95% CI: 8.6-21.6). Grade ≥3 treatment-related adverse events occurred in 39.3% of patients, with no treatment-related deaths. The study concluded that surufatinib-toripalimab combination showed signal-generating activity with manageable toxicity, warranting further investigation in larger populations.
10.1007/s00262-026-04419-7
Jun 08 – Jun 15, 2026
Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors.
CLIN CANCER RES · Q1 JOURNAL - RANK #29/326TOP-TIER
This prospective, first-in-human Phase I trial assessed the oral CDC2-like kinase inhibitor rogocekib (CTX-712) in 46 adults with advanced, relapsed, or refractory solid tumors. Using an accelerated titration followed by a 3 + 3 dose-escalation (10–175 mg twice weekly) and three dose-expansion cohorts (105 mg BIW, 70 mg BIW, 105 mg QW), investigators determined the maximum tolerated dose at 140 mg BIW and identified dose-limiting toxicities of thrombocytopenia with hypokalemia and dehydration. Pharmacokinetics were dose-proportional, and pharmacodynamic assays (THAP9-AS1, S6K) indicated target engagement; partial responses occurred in 3/46 patients (6.5 %), all with ovarian cancer. Despite two treatment-related deaths, most adverse events (chiefly nausea, vomiting, diarrhea) were manageable, supporting further clinical development of rogocekib.
10.1158/1078-0432.CCR-25-4896
Jun 01 – Jun 08, 2026
Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial.
NAT CANCER · Q1 JOURNAL - RANK #11/326TOP-TIER
This multicenter phase 1 study evaluated intraventricular nivolumab in patients with leptomeningeal metastatic disease (LMD) from solid tumors who were eligible for intravenous PD-1/PD-L1 therapy or had high tumor mutational burden. Participants were enrolled in four dose-escalation cohorts (20, 30, 40, 50 mg) to assess safety, with an independent data safety monitoring board reviewing each cohort before escalation. Of 24 participants who received treatment, one dose-limiting toxicity occurred at 40 mg, leading to a recommended fixed dose of 50 mg, while median overall survival was 6.6 months (6-, 12-, 18-month OS rates were 55.0%, 33.3%, and 16.7%, respectively). The investigators concluded that intraventricular nivolumab is safe and feasible for further evaluation.
10.1038/s43018-026-01185-4
Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial.
CLIN CANCER RES · Q1 JOURNAL - RANK #29/326TOP-TIER
The LuMIERE trial is a prospective, open-label, non-randomized phase I/II clinical study evaluating the safety and efficacy of radiopharmaceutical therapy [177Lu]Lu-FAP-2286 in heavily pretreated patients with advanced solid tumors. Phase I employed a Bayesian optimal interval design to assess dosage-limiting toxicities (DLTs) across four dosage levels (3.70–9.25 GBq), administered intravenously every six weeks for up to six cycles. Two DLTs were reported, with one Grade 4 lymphopenia and one Grade 3 hemoptysis at doses of 5.55 GBq and 9.25 GBq, respectively, and the recommended phase II dose (RP2D) was identified as 9.25 GBq. Efficacy data showed one partial response and stable disease in 10 patients, warranting further investigation in phase II studies.
10.1158/1078-0432.CCR-25-4356